 Connection
Ross Kedl to Cancer Vaccines
This is a "connection" page, showing publications Ross Kedl has written about Cancer Vaccines.
|
|
| |
Connection Strength |
|
 |
|
 |
| |
0.781 |
|
|
|
-
Pennock ND, Kedl JD, Kedl RM. T Cell Vaccinology: Beyond the Reflection of Infectious Responses. Trends Immunol. 2016 Mar; 37(3):170-180.
Score: 0.444
-
Kemmler CB, Clambey ET, Kedl RM, Slansky JE. Elevated tumor-associated antigen expression suppresses variant peptide vaccine responses. J Immunol. 2011 Nov 01; 187(9):4431-9.
Score: 0.082
-
Ahonen CL, Wasiuk A, Fuse S, Turk MJ, Ernstoff MS, Suriawinata AA, Gorham JD, Kedl RM, Usherwood EJ, Noelle RJ. Enhanced efficacy and reduced toxicity of multifactorial adjuvants compared with unitary adjuvants as cancer vaccines. Blood. 2008 Mar 15; 111(6):3116-25.
Score: 0.064
-
Jordan KR, McMahan RH, Oh JZ, Pipeling MR, Pardoll DM, Kedl RM, Kappler JW, Slansky JE. Baculovirus-infected insect cells expressing peptide-MHC complexes elicit protective antitumor immunity. J Immunol. 2008 Jan 01; 180(1):188-97.
Score: 0.063
-
McWilliams JA, McGurran SM, Dow SW, Slansky JE, Kedl RM. A modified tyrosinase-related protein 2 epitope generates high-affinity tumor-specific T cells but does not mediate therapeutic efficacy in an intradermal tumor model. J Immunol. 2006 Jul 01; 177(1):155-61.
Score: 0.057
-
Zaks K, Jordan M, Guth A, Sellins K, Kedl R, Izzo A, Bosio C, Dow S. Efficient immunization and cross-priming by vaccine adjuvants containing TLR3 or TLR9 agonists complexed to cationic liposomes. J Immunol. 2006 Jun 15; 176(12):7335-45.
Score: 0.057
-
U'Ren L, Kedl R, Dow S. Vaccination with liposome--DNA complexes elicits enhanced antitumor immunity. Cancer Gene Ther. 2006 Nov; 13(11):1033-44.
Score: 0.014
|
Connection Strength
The connection strength for concepts is the sum of the scores for each matching publication.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
|